Research programme: oral formulation therapeutics - Orexo

Drug Profile

Research programme: oral formulation therapeutics - Orexo

Alternative Names: OX382

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orexo
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 30 Sep 2017 Orexo files a patent application for OX382
  • 11 Jul 2017 Orexo plans a phase I trial of OX 382 in Undefined indication in Sweden in the first quarter of 2018
  • 11 Jul 2017 Early research in Undefined indication in Sweden (Sublingual), before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top